Latest news with #Sanuwave
Business Insider
7 days ago
- Business
- Business Insider
Sanuwave Health reports Q2 EPS 1c vs $1.77 last year
Reports Q2 revenue $10.2M vs $7.2M last year. 'We're pleased to have put up strong results for Q2 and to have achieved 51% revenue growth in the first six months of 2025 vs the same period in 2024 ,' said Morgan Frank, CEO. 'We sold 214 UltraMIST systems in the first six months of this year, more than we did in the full year of 2023 and an increase of 86% versus same period in 2024. Q1 and Q2 have been spent building and reshaping our sales and commercial operations teams, and as of mid July, the Company achieved full national sales coverage for the first time in my tenure as CEO. If Q1 and Q2 were the quarters of 'max disruption' Q3 is expected to be the quarter of 'max construction' as the Company builds up momentum around our new sales and marketing practices (including the launch of our first concerted marketing program) with an aim to set us up for breakout performance in Q4 2025 and 2026. The energy at our sales and commercial operations national meeting a couple of weeks ago was palpable. I think we're all looking forward to seeing what Sanuwave can become as it starts firing on all cylinders.' Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yahoo
28-05-2025
- Business
- Yahoo
Sanuwave Health Selected for Inclusion in Russell 2000® Index
EDEN PRAIRIE, Minn., May 28, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (NASDAQ: SNWV), a leading provider of next-generation, non-invasive wound care solutions, today announced, as part of the 2025 Russell indexes reconstitution, the Company's inclusion in the Russell 2000® Index. This will be effective after the U.S. market opens on June 30. In addition to the Russell 2000® Index, the Company is also expected to be included in the broader Russell 3000® Index and in the Russell Microcap® Index. The annual reconstitution of the Russell U.S. indexes captures the 4,000 largest U.S. stocks as of April 30, ranked by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, results in automatic inclusion in either the Russell 1000® Index or the Russell 2000® Index, as well as the appropriate growth and value style indexes. FTSE Russell determines index membership primarily by objective, market-capitalization rankings and style attributes. The Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. As of June 2024, approximately $10.6 trillion in assets were benchmarked to the Russell U.S. indexes, which are maintained by FTSE Russell, a leading global index provider. For more information about the Russell indexes and the annual reconstitution process, please visit the 'Russell Reconstitution' section on the FTSE Russell website. About Sanuwave Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body's normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular press release may contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in tariff rates. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company's ability to manage its capital resources, competition and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement. Contact: investors@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-05-2025
- Business
- Yahoo
Sanuwave Health Appoints Greg Bazar to Board of Directors
Bazar brings decades of experience in engineering, computer science and cyber security, AI, and business intelligence over a career of building successful companies EDEN PRAIRIE, Minn., May 28, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave') (Nasdaq:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the addition of Greg Bazar to its Board of Directors. Bazar brings decades of leadership experience in engineering, technology, and cybersecurity to Sanuwave's Board of Directors. He currently serves as Chairman of the Board at Simpatico Systems, a company he founded to deliver advanced IT and cybersecurity solutions. Previously, he was the first employee at intelligent connectivity provider 3D-P, where he played a pivotal role in the company's growth and strategic direction, ultimately becoming Chairman of the Board and leading it through its acquisition by Epiroc, a global leader in mining and infrastructure solutions. Greg began his career at Caterpillar, gaining global experience in leveraging technology to enhance human innovation. He holds a degree in engineering from the Colorado School of Mines. 'All of the interesting parts of the future are interdisciplinary; this is why Sanuwave focuses on finding drivers and leaders with unusual Venn overlaps in their experience and talents. Greg fits this mold, bringing expertise in a variety of disciplines that will be important to our future roadmap as well as a proven track record of the culture building that makes for successful companies,' said Sanuwave CEO Morgan Frank. 'He's 'one of us' and we look forward to working with him on our mission to revolutionize complex wound care.' "From engineering to cybersecurity, I've always been drawn to smart solutions. Sanuwave's healing technology is brilliant, and as it evolves beyond therapeutics and into informational ecosystems, this is clearly the way forward. Let's make some noise—and some progress!" Greg joined the Sanuwave board on May 27, 2025. The Company also announced that long-time board member Michael Stolarski will be stepping down in order to spend more (much needed) time with his golf game and eating fancy things. 'Mike has been a Sanuwave stalwart since the early days, and we thank him for his inestimable contributions and good humor over the years,' said Morgan Frank. 'We'll miss ya, buddy.' Mr Stolarski has agreed to remain a consultant to the Company to provide continuity and to assist in the transition. About Sanuwave Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body's normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular press release may contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in tariff rates. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company's ability to manage its capital resources, competition and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement. Contact: investors@
